SV ABOUT ALLIGATOR RESEARCH & DEVELOPMENT CORPORATE GOVERNANCE INVESTORS NEWS CONTACT Preferential Rights Issue Q4 2021 Start > Investors > Preferential Rights Issue Q4 2021 Share and shareholders Calendar Analysts IPO Financial reports Preferential rights issue Q1 2021 Preferential Rights Issue Q4 2021 Presentations The offering in summary Alligator Bioscience announced on October 7, 2021 its decision to perform a preferential rights issue, subject to the subsequent approval of the Extra General Meeting. Preliminary timeline November 8, 2021 - Extraordinary General Meeting for, inter alia, approval of preferential rights issue November 8, 2021 - Last day of trading incl. preferential rights November 9, 2021 - Publication of prospectus November 9, 2021 – First day of trading excl. preferential rights November 10, 2021 – Record date November 12 – November 23, 2021 – Trading in rights November 12 – November 26, 2021 – Subscription period November 12, 2021 – Until the Rights Issue is registered at the Swedish Companies Registration Office – Trading in paid subscription share (Sw. “BTA”) December 1, 2021 – Estimated publication of outcome of Rights Issue Prospectus Prospectus: Invitation to subscribe for shares in Alligator Bioscience AB (publ) Prospectus: Supplement (2 Dec 2021) Brochure: Offering in summary Financial Reports & Other Documentation Application form without subscription rights Interim report January - September 2021 Annual report 2020 Annual report 2019 Articles of Association Certificate of registration Alligator Bioscience AB Pressreleases December 1, 2021 - Alligator announces final outcome of rights issue November 29, 2021 - Alligator announces preliminary outcome of rights issue November 9, 2021 - Alligator Bioscience publishes prospectus in connection with forthcoming rights issue November 8, 2021 - Bulletin from the extraordinary general meeting in Alligator Bioscience AB October 7, 2021 - Notice of Extraordinary General Meeting in Alligator Bioscience AB October 7, 2021 - Alligator carries out a fully guaranteed Rights Issue of approximately SEK 257m About Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. Links About Alligator Research and development Corporate governance Investors News Contact Privacy policy Contact Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden Phone: + 46 (0)46 540 82 00 info@alligatorbioscience.com ir@alligatorbioscience.com Subscribe Subscribe to get our pressreleases by email. SUBSCRIBE © Copyright 2018 - Alligator Bioscience AB IMPORTANT INFORMATION Due to legal restrictions, the information on this part of Alligator Bioscience AB’s (”Alligator”) website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page. The information contained in this section of Alligator’s website is not intended for, and must not be accessed by, distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States, Canada, New Zealand, South Africa, Japan, Australia, South Korea, Hong Kong, Switzerland, Singapore or any other jurisdiction where distribution would require additional prospectuses, registration measures or other measures besides those required by Swedish or otherwise would be in conflict with the rules of such jurisdiction or which cannot be made without application of exemptions in such jurisdictions. The information on the websites does not constitute any offer regarding subscription rights, paid subscribed shares or shares in Alligator (“Securities”) to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements. No Securities have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States and may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States. Within the European Economic Area (“EEA”), no public offering of Securities is made in other countries than Sweden. In other member states of the European Union (“EU”), such an offering of Securities may only be made in accordance with the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law. In order to be eligible to view the information on the following web page, you shall be deemed, by accessing the following web page, to have confirmed and represented that (i) you have read and accepted the terms and restrictions set out above, and (ii) you are not located in the United States, Canada, New Zealand, South Africa, Japan, Australia, South Korea, Hong Kong, Switzerland, Singapore or in any other jurisdiction where the release, distribution or publication of the information would be unlawful according to applicable law or regulations. I ACCEPT I DO NOT ACCEPT